Metabolic regulation of magnolol on the nuclear receptor, liver X receptor

Xie,Na; Hu,Chunyang; Guo,Anran; Liang,Hao; Du,Pengcheng; Yin,Guotian

doi:10.3892/etm.2015.2300

Metabolic regulation of magnolol on the nuclear receptor, liver X receptor

Authors:
- Na Xie
- Chunyang Hu
- Anran Guo
- Hao Liang
- Pengcheng Du
- Guotian Yin
View Affiliations

Affiliations: Department of Cardiology, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453000, P.R. China, Department of Internal Medicine, Luyi Xian People's Hospital, Zhoukou, Henan 477200, P.R. China
Published online on: February 17, 2015 https://doi.org/10.3892/etm.2015.2300
Pages: 1827-1830

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate whether magnolol, the essential component of the traditional Chinese medicine, Magnolia officinalis, can pass through liver X receptor α (LXRα), to subsequently play an important role in the lipid metabolic balance. Using a HepG2 human hepatoma cell line, mammalian cellular one‑hybridization and mammalian cell transcriptional activation experiments were performed to detect the combination degree of magnolol at different concentrations with LXRα, and assess the transcriptional activity. In addition, using a THP‑1 human monocytic cell line, quantitative polymerase chain reaction was performed to assess the effect on the expression levels of downstream genes. Magnolol was shown to dose‑dependently combine with LXRα, and subsequently regulate the transcriptional activity of LXRα. In addition, magnolol was found to adjust the expression of associated LXRα downstream genes in the macrophages. In conclusion, magnolol was demonstrated to affect LXRα, which may outline a new molecular mechanism through which magnolol exerts a lipid‑lowering function.

View Figures

View References

1	Lozano R, Naghavi M, Foreman K, et al: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 380:2095–2128. 2012. View Article : Google Scholar : PubMed/NCBI
2	Vacca M, Degirolamo C, Mariani-Costantini R, Palasciano G and Moschetta A: Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome. Wiley Interdiscip Rev Syst Biol Med. 3:562–587. 2011. View Article : Google Scholar : PubMed/NCBI
3	Calkin AC and Tontonoz P: Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol. 13:213–224. 2012.PubMed/NCBI
4	Chawla A, Boisvert WA, Lee CH, et al: A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 7:161–171. 2001. View Article : Google Scholar : PubMed/NCBI
5	Venkateswaran A, Laffitte BA, Joseph SB, et al: Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA. 97:12097–12102. 2000. View Article : Google Scholar : PubMed/NCBI
6	Naik SU, Wang X, Da Silva JS, et al: Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation. 113:90–97. 2006. View Article : Google Scholar : PubMed/NCBI
7	Sun AL, Feng L and Liu RM: Preparative isolation and purification of honokiol and magnolol from Magnolia officinalis Rehd. et Wils by high-speed countercurrent chromatography. Fen Xi Hua Xue Bian Ji Bu. 33:1016–1018. 2005.[(In Chinese)].
8	Wang ZQ, Mi W, Liu XB, et al: The in vitro growth-inhibitory effect of Magnolia officinalis Rehd. et Wils. (MOR) on bacteria. Shizhen Guo Yi Guo Yao. 18:27632007.[(In Chinese)].
9	Zhang WW, Li Y, Wang XQ, et al: Effects of magnolol and honokiol derived from traditional Chinese herbal remedies on gastrointestinal movement. World J Gastroenterol. 11:4414–4418. 2005.PubMed/NCBI
10	Ren SC, Fan YC and Li CC: Inhibitory effects of 30 kinds of Chinese herbal medicine on fungi in food. Adv Mater Res. 343-344:737–742. 2012.
11	Yang QH, Yang HW, Xie F and Zhang YP: Experimental study of Jiangzhi Ninggan capsules on rat model with fatty liver disease. Liaoning Zhong Yi Zazhi Bianji Bu. 35:1420–1422. 2008.[(In Chinese)].
12	Kotani H, Tanabe H, Mizukami H, Amagaya S and Inoue M: A naturally occurring rexinoid, honokiol, can serve as a regulator of various retinoid x receptor heterodimers. Biol Pharm Bull. 35:1–9. 2012. View Article : Google Scholar : PubMed/NCBI
13	Houck KA, Borchert KM, Hepler CD, Thomas JS, Bramlett KS, Michael LF and Burris TP: T0901317 is a dual LXR/FXR agonist. Mol Genet Metab. 83:184–187. 2004. View Article : Google Scholar : PubMed/NCBI
14	Chen CR, Tan R, Qu WM, et al: Magnolol, a major bioactive constituent of the bark of Magnolia officinalis, exerts antiepileptic effects via the GABA/benzodiazepine receptor complex in mice. Br J Pharmacol. 164:1534–1546. 2011. View Article : Google Scholar : PubMed/NCBI
15	Kumar S, Guru SK, Pathania AS, Kumar A, Bhushan S and Malik F: Autophagy triggered by magnolol derivative negatively regulates angiogenesis. Cell Death Dis. 4:e8892013. View Article : Google Scholar : PubMed/NCBI
16	Zhang Y and Tang F: Advance in latest studies on pharmacological effects of magnolol. Zhongguo Zhong Yao Za Zhi. 37:3526–3530. 2012.[(In Chinese)]. PubMed/NCBI
17	Lee YJ, Lee YM, Lee CK, Jung JK, Han SB and Hong JT: Therapeutic applications of compounds in the Magnolia family. Pharmacol Ther. 130:157–176. 2011. View Article : Google Scholar : PubMed/NCBI
18	Vaughan AM and Oram JF: ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL. J Lipid Res. 47:2433–2443. 2006. View Article : Google Scholar : PubMed/NCBI
19	Grefhorst A, Oosterveer MH, Brufau G, Boesjes M, Kuipers F and Groen AK: Pharmacological LXR activation reduces presence of SR-B1 in liver membranes contributing to LXR-mediated induction of HDL-cholesterol. Atherosclerosis. 222:382–389. 2012. View Article : Google Scholar : PubMed/NCBI
20	Wang X and Paigen B: Genetics of variation in HDL cholesterol in humans and mice. Circ Res. 96:27–42. 2005. View Article : Google Scholar : PubMed/NCBI
21	Yasuda T, Grillot D, Billheimer JT, Briand F, Delerive P, Huet S and Rader DJ: Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol. 30:781–786. 2010. View Article : Google Scholar : PubMed/NCBI
22	Linsel-Nitschke P and Tall AR: HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov. 4:193–205. 2005. View Article : Google Scholar : PubMed/NCBI
23	Degoma EM and Rader DJ: Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol. 8:266–277. 2011. View Article : Google Scholar : PubMed/NCBI